Ahmed AlBadri

Ahmed AlBadri

Auto-generated profile, based on publicly available information

Ahmed AlBadri

Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2023 in JACC
Verified
Journal Article
Closed access
BSBruce A. Samuels
Bruce A. Samuels
SSSamit Shah
Samit Shah
RWRobert Jay Widmer
Robert Jay Widmer
YKYuhei Kobayashi
Yuhei Kobayashi
SMSteven E.S. Miner
Steven E.S. Miner
JTJennifer A. Tremmel
Jennifer A. Tremmel

11 September 2023 in JACC
Verified
Journal Article
Closed access
NSNathaniel R. Smilowitz
Nathaniel R. Smilowitz
MPMegha Prasad
Megha Prasad
RWRobert Jay Widmer
Robert Jay Widmer
OTOlga Toleva
Olga Toleva
OQOdayme Quesada
Odayme Quesada
JTJennifer A. Tremmel
Jennifer A. Tremmel

21 April 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
AAAhmed Al‐Badri
Ahmed Al‐Badri
ATAyman Samman Tahhan
Ayman Samman Tahhan
NSNabil Sabbak
Nabil Sabbak
AAAyman Alkhoder
Ayman Alkhoder
CLChang Liu
Chang Liu
AQArshed Ali Quyyumi
Arshed Ali Quyyumi
Background: Multiple biomarkers have been independently and additively associated with major adverse cardiovascular events in patients with coronary artery disease. We investigated the prognostic value of suPAR (soluble urokinase‐type plasminogen activator receptor) and hsTnI (high‐sensitivity troponin I) levels in symptomatic patients with no obstructive coronary artery disease. We hypothesized that high levels of these biomarkers will be associated with the risk of future adverse outcomes. Methods and Results: Plasma levels of suPAR and hsTnI were measured in 556 symptomatic patients with no obstructive coronary artery disease. A biomarker risk score was calculated by counting the number of biomarkers above the median in this cohort (suPAR>2523 pg/mL and hsTnI>2.7 pg/mL). Survival analyses were performed with models adjusted for traditional risk factors. All‐cause death and major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, and heart failure) served as clinical outcomes over a median follow‐up of 6.2 years. Mean age was 57±10 years, 49% of the cohort patients were female, and 68% had a positive stress test. High suPAR and hsTnI levels were independent predictors of all‐cause death (hazard ratio=3.2 [95% CI, 1.8–5.7] and 1.3 [95% CI, 1.0–1.7], respectively; both P <0.04) and major adverse cardiovascular events (hazard ratio=2.7 [95% CI, 1.4–5.4] and 1.5 [95% CI, 1.2–2.0], respectively; both P <0.002). Compared with a biomarker risk score of 0, biomarker risk scores of 1 and 2 were associated with 19‐ and 14‐fold increased risk of death and development of major adverse cardiovascular events, respectively. Conclusions: Among symptomatic patients with no obstructive coronary artery disease, higher levels of suPAR and hsTnI were independently and additively associated with an increased risk of adverse events. Whether modification of these biomarkers will improve risk in these patients needs further investigation.

13 March 2023 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
AAAhmed AlBadri
Ahmed AlBadri
JJJubin Joseph
Jubin Joseph
VPVivek Patel
Vivek Patel
DPDhairya Patel
Dhairya Patel
OFIR KORENOFIR KOREN
OFIR KOREN
RMRaj Makkar
Raj Makkar

12 June 2017 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
AAAhmed AlBadri
Ahmed AlBadri
DLDerek Leong
Derek Leong
C. Noel Bairey MerzC. Noel Bairey Merz
C. Noel Bairey Merz
JWJanet Wei
Janet Wei
EHEileen M. Handberg
Eileen M. Handberg
CPCarl J Pepine
Carl J Pepine
Background: Typical angina (TA) is defined as substernal chest pain precipitated by physical exertion or emotional stress and relieved with rest or nitroglycerin. Women and elderly patients are usually have atypical symptoms both at rest and during stress, often in the setting of nonobstructive coronary artery disease (CAD).Hypothesis: To further understand this, we performed subgroup analysis comparing subjects who presented with TA vs nontypical angina (NTA) using baseline data of patients with nonobstructive CAD and coronary microvascular dysfunction (CMD) enrolled in a clinical trial.Methods: 155 subjects from the RWISE study were divided into 2 groups based on angina characteristics: TA (defined as above) and NTA (angina that does not meet criteria for TA). Coronary reactivity testing (responses to adenosine, acetylcholine, and nitroglycerin), cardiac magnetic resonance–determined myocardial perfusion reserve index (MPRI), baseline Seattle Angina Questionnaire (SAQ), and Duke Activity Status Index (DASI) scores were evaluated.Results: The mean age was 55 ± 10 years; Overall, 30% of subjects had TA. Baseline shortness of breath, invasively assessed acetylcholine‐mediated coronary endothelial function, and SAQ score were worse in the TA group (all P < 0.05), whereas adenosine‐mediated coronary flow reserve, MPRI, and DASI score were similar to the NTA group.Conclusions: Among subjects with CMD and no obstructive CAD, those with TA had more angina pectoris, shortness of breath, and worse quality of life, as well as more severe coronary endothelial dysfunction. Typical angina in the setting of CMD is associated with worse symptom burden and coronary endothelial dysfunction. These results indicate that TA CMD subjects represent a relatively new CAD phenotype for future study and treatment trials.

1 September 2023 in EuroIntervention
Verified
Journal Article
Open access
TCTarun Chakravarty
Tarun Chakravarty
MMMoody Makar
Moody Makar
AAAhmed Al-Badri
Ahmed Al-Badri
ALAndrew Luxhoj
Andrew Luxhoj
RMRaj R. Makkar
Raj R. Makkar
Case report of unsuccessful MitraClip TEER for severe mitral regurgitation due to inability to correct trajectory, but successful PASCAL TEER two months later through same access site in the same patient.